Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Locally Advanced Rectal Cancer × sintilimab × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 10 Stomach Neoplasms 8 Carcinoma, Non-Small-Cell Lung 5 Pancreatic Neoplasms 3 Esophageal Neoplasms 3 Colorectal Neoplasms 3 Uterine Cervical Neoplasms 2 Triple Negative Breast Neoplasms 2 Rectal Neoplasms 2 Neoplasm Metastasis 2 Nasopharyngeal Carcinoma 2 Esophageal Squamous Cell Carcinoma 2 Endometrial Neoplasms 2 Thyroid Neoplasms 1 Solid Tumor 1 Recurrence 1 Pancreatic Cancer Resectable 1 Pancreatic Cancer Metastatic 1 Neuroblastoma 1 Neoplasms, Unknown Primary 1 Neoplasms 1 Metastatic Gastroesophageal Junction Adenocarcinoma 1 Lung Squamous Cell Carcinoma 1 Locally Recurrent Rectal Cancer 1 Locally Advanced Rectal Cancer (LARC) 1 Locally Advanced Rectal Cancer 1 Localized Advanced Rectal Adenocarcinoma 1 Liver Neoplasms 1 Hemangiosarcoma 1 Gastric Adenocarcinoma 1

Interventions

Capecitabine 7 Oxaliplatin 5 Fluorouracil 3 tislelizumab 2 spartalizumab 2 Leucovorin 2 Irinotecan 2 toripalimab 1 sintilimab 1 irinotecan sucrosofate 1 camrelizumab 1 Thymalfasin 1 Radiotherapy, Intensity-Modulated 1 Radiation 1 Folfox protocol 1 Celecoxib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06493240 2025-11-25

NLCCRIT-LARC

Peking University People's Hospital

Phase 2 Completed

Gastrointestinal

Locally Advanced Rectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡